Form 4: Illumina SVP, Chief Technology Officer Steven Barnard Reports Changes in Beneficial Ownership

Steven Barnard, SVP and Chief Technology Officer of Illumina, reports acquisition of restricted stock units and performance shares, along with shares acquired through the Employee Stock Purchase Plan.

Summary

• On March 5, 2025, Steven Barnard, SVP, Chief Technology Officer of Illumina, reported changes in beneficial ownership.
• Barnard acquired 8,123 shares of common stock through a grant of restricted stock units, which will vest in four equal installments on February 15 of 2026, 2027, 2028, and 2029.
• He also acquired 192 shares through the Employee Stock Purchase Plan.
• Additionally, Barnard acquired 9,477 performance shares tied to the company's three-year average operating margin for fiscal years 2025-2027, vesting on January 2, 2028.
• Another 9,477 performance shares were acquired, linked to Illumina's relative total shareholder return for the fiscal year ending January 2, 2028.
• The number of shares issued for both performance share grants will range from 0% to 250% of the specified amount, based on the company's performance relative to pre-defined objectives.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and aligns executive interests with company performance. There are no explicit negative indicators.

Positives

• The acquisition of shares through restricted stock units and performance shares aligns the executive's interests with the company's long-term performance.
• Participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Risks

• The actual number of performance shares that will vest is contingent on the company's performance against pre-defined objectives, introducing uncertainty.

Future Outlook

The vesting of restricted stock units and performance shares is contingent upon continued service and the company's performance relative to pre-defined objectives.

Industry Context

This filing is a routine disclosure of stock-based compensation for a key executive, a common practice in publicly traded companies to incentivize and retain talent.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among companies in the biotechnology industry, including competitors like Thermo Fisher Scientific, Danaher, and Agilent Technologies.
• The vesting schedules and performance metrics used by Illumina are typical for executive compensation packages in this sector.

Stakeholder Impact

• Shareholders may view the stock grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may be motivated by the opportunity to participate in the Employee Stock Purchase Plan.

Key Dates